A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-007-0524-6PMID 17569043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• A phase II study of gemcitabine and capecitabine in metastatic renal cancer

  2006cited by this paper
• A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

  2005cited by this paper
• Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.

  2005cited by this paper
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

  2005cited by this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cited by this paper
• GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

  2003influential reference
• Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

  2003cited by this paper
• The role of systemic chemotherapy in the treatment of kidney cancer.

  2003cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.

  1997cited by this paper
• Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy.

  1996cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Evaluation of low dose continuous infusion 5‐fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

  1994cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989influential reference

• Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy

  2022cites this paper
• RRM2 Regulates Sensitivity to Sunitinib and PD‐1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway

  2021cites this paper
• Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation

  2021cites this paper
• Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

  2021cites this paper
• The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments

  2021cites this paper
• Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.

  2020cites this paper
• A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors

  2018cites this paper
• The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma

  2018cites this paper
• The promoted delivery of RRM2 siRNA to vascular smooth muscle cells through liposome-polycation-DNA complex conjugated with cell penetrating peptides.

  2018cites this paper
• Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides

  2018cites this paper
• Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma

  2017cites this paper
• Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

  2017cites this paper
• A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

  2016cites this paper
• RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

  2016cites this paper
• Nucleotide metabolism, oncogene-induced senescence and cancer.

  2015cites this paper
• HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma.

  2014cites this paper
• A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

  2013influential citation
• Chemotherapy in metastatic renal cell carcinoma today? A systematic review

  2013cites this paper
• Target mRNA inhibition by oligonucleotide drugs in man

  2012cites this paper
• 核糖核苷酸还原酶和非小细胞肺癌

  2012cites this paper
• Recently published works.

  2011cites this paper
• Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2

  2011cites this paper
• GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.

  2009cites this paper
• Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

  2009cites this paper
• Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response*

  2009cites this paper
• A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels

  2009cites this paper
• Recent progress in oligonucleotide therapeutics: antisense to aptamers

  2008cites this paper
• Pharmacokinetic-Pharmacodynamic Studies Of 5-Azacytidine In Combination With Gti-2040

  2008cites this paper